FIA
NBSE

FNY Investment Advisers’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

FNY Investment Advisers’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-750
Closed -$122K – 943
2020
Q3 		$113K Buy
+750
New +$122K 0.05% 210
2020
Q2 		– Sell
-564
Closed -$80K – 630
2020
Q1 		$80K Buy
564
+531
+1,609% +$70.3K 0.06% 196
2019
Q4 		$4K Sell
33
-832
-96% -$97.6K ﹤0.01% 708
2019
Q3 		$86K Sell
865
-661
-43% -$65.3K 0.03% 330
2019
Q2 		$104K Buy
+1,526
New +$86.4K 0.03% 244

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

FNY Investment Advisers's NBSE Position: Q4 2020 in Review

FNY Investment Advisers sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2020, closing a stake of 750 shares — an estimated $122K sold.

FNY Investment Advisers first reported a position in NBSE in Q2 2019 and held it in 5 quarters. The position peaked at $113K in Q3 2020. 53 funds tracked by Wall St. Rank hold NBSE as of Q4 2020.

  • FNY Investment Advisers reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • FNY Investment Advisers sold 750 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $122K.
  • FNY Investment Advisers first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
  • FNY Investment Advisers's NeuBase Therapeutics, Inc. Common Stock position peaked at $113K in Q3 2020.
  • 53 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2020.

Based on FNY Investment Advisers's 13F filing for Q4 2020, filed 19 Jan 2021.